Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon gamma for prevention of secondary infections in ICU-acquired sustained immunosuppression
2024-516780-93-00Phase 3Authorised
- Sponsor
- CHU de Limoges
- Start
- Jul 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of interferon gamma-1b in immunocompromise and Infection (2 arms), sponsored by CHU de Limoges. Primary endpoint: Incidence of secondary infection episodes at Day 90. Planned start Jul 2025; status: authorised.
02
Drugs
interferon gamma-1b
03
Conditions
immunocompromiseInfection
Beyond the preview
Go deeper on 2024-516780-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516780-93-00.